Oxalic Acid Cocrystal Form for Stable Kinase Inhibitor Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The identification and development of stable and effective solid forms of pharmaceutical compounds, such as (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, are challenging due to unpredictable polymorphism and the lack of predictive methods for crystalline forms, affecting properties like stability and bioavailability.
Innovation Solution
The development of specific solid forms, including cocrystals with oxalic acid, characterized by X-ray powder diffraction patterns, thermogravimetric analysis, and differential scanning calorimetry, providing stability and solubility profiles, suitable for treating conditions related to kinase pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If multiple-component solids (salts, cocrystals, solvates) are developed to improve physical properties, then stability and solubility are enhanced, but the complexity of solid form identification and selection increases
Solution Approach 1:
The patent employs computational chemistry tools and predictive algorithms as intermediaries to bridge the gap between desired solid form properties and actual crystalline structures. These computational models predict stable solid forms before synthesis, reducing the complexity of identifying and selecting appropriate polymorphs and salt forms while ensuring stability and solubility improvements.
Solution Approach 2:
The invention systematically varies multiple parameters including molecular structure, crystal lattice arrangement, solvent composition, and temperature conditions to optimize solid form properties. By changing these parameters in a controlled manner guided by computational predictions, the patent achieves enhanced stability and solubility while managing the complexity through structured parameter optimization.
2Stability of the object's composition
If crystalline forms are developed to improve physical stability, then chemical stability is enhanced, but prediction of crystalline forms becomes more difficult
Solution Approach 1:
The patent replaces traditional trial-and-error experimental approaches with computational chemistry methods. Quantum mechanical calculations, molecular dynamics simulations, and machine learning algorithms predict crystalline forms and their stability before synthesis, eliminating the need for extensive experimental screening and making the prediction process more reliable and less difficult.
Solution Approach 2:
The invention implements iterative feedback loops where computational predictions are validated against experimental data, and the models are continuously refined. This feedback mechanism improves the accuracy of crystalline form prediction over time, making it easier to identify stable crystalline structures while maintaining high chemical stability.
3Productivity
If amorphous solids are used to enhance dissolution profile, then bioavailability is improved, but physical stability decreases
Solution Approach 1:
The patent develops composite solid forms combining amorphous and crystalline regions within the same material structure. These composite solids leverage the high dissolution rate of amorphous regions while the crystalline network provides physical stability. The computational tools optimize the composition and distribution of these phases to achieve both improved bioavailability and maintained stability.
Solution Approach 2:
The invention applies different structural characteristics to different regions of the solid form. Amorphous regions are positioned where rapid dissolution is needed, while crystalline regions are located to provide structural stability. This spatial differentiation of material properties allows simultaneous optimization of dissolution rate and physical stability through controlled local quality variations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These solid forms enhance the therapeutic efficacy by improving stability and solubility, enabling effective treatment of cancers and kinase pathway-related disorders, including B-cell proliferative diseases.
Implementation Method 1
solid forms comprising (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide and oxalic acid
Implementation Method 2
crystalline molecular complexes of two or more non-volatile compounds bound together in a crystal lattice by non-ionic interactions
Implementation Method 3
characterized by X-ray powder diffraction patterns
Implementation Method 4
X-ray powder diffraction pattern comprising characteristic X-ray powder diffraction peaks
Implementation Method 5
thermogravimetric analysis, and differential scanning calorimetry, providing stability and solubility profiles
Implementation Method 6
differential scanning calorimetry, providing stability and solubility profiles
Data Source
AI summary
Provided herein are formulations, processes, solid forms and methods of use relating to (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide.


